Dan Xie

发表

AAV8-Mediated Long-Term Expression of Human LCAT Significantly Improves Lipid Profiles in hCETP;Ldlr+/− Mice

T. Vogt, Vinit Shah, J. Castro-Pérez, 2011, Journal of cardiovascular translational research.

The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides

P. Griffin, N. Thornberry, J. Fenyk-Melody, 2003, Journal of Biological Chemistry.

A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects.

D. Moller, V. Ding, S. Qureshi, 2004, Diabetes.

Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor.

V. Ding, S. Qureshi, D. Szalkowski, 2005, Bioorganic & medicinal chemistry letters.

Detection of Glucagon-Dependent GTPγS Binding in High-Throughput Format

S. Qureshi, Bei B. Zhang, Q. Dallas-yang, 2002 .

Regulation of insulin signal transduction pathway by a small-molecule insulin receptor activator.

D. Moller, D. E. Biazzo-Ashnault, V. Ding, 2002, The Biochemical journal.

Evaluation of CETP activity in vivo under non-steady-state conditions: influence of anacetrapib on HDL-TG flux[S]

M. Cleary, G. Opiteck, D. Johns, 2016, Journal of Lipid Research.

Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors.

Michael E. Lassman, Shirly Pinto, M. Garcia-Calvo, 2012, Bioorganic & medicinal chemistry letters.

Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors.

Michael E. Lassman, Shirly Pinto, M. Garcia-Calvo, 2011, Bioorganic & medicinal chemistry letters.

A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluation.

Michael E. Lassman, Shirly Pinto, J. Lisnock, 2012, Bioorganic & medicinal chemistry letters.

A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanes.

Michael E. Lassman, Shirly Pinto, J. Lisnock, 2012, Bioorganic & medicinal chemistry letters.

Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine.

Michael E. Lassman, Shirly Pinto, M. Garcia-Calvo, 2012, Bioorganic & medicinal chemistry letters.

The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors.

Michael E. Lassman, Shirly Pinto, M. Garcia-Calvo, 2012, Bioorganic & medicinal chemistry letters.

Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques.

M. Cleary, D. Johns, T. Roddy, 2014, European journal of pharmacology.

Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein.

A. Peier, D. Johns, Sheng-ping Wang, 2013, Biochimica et biophysica acta.

Peptidomic profiling of human cerebrospinal fluid identifies YPRPIHPA as a novel substrate for prolylcarboxypeptidase

Michael E. Lassman, Shirly Pinto, N. Yates, 2010, Proteomics.

Activation of Insulin Signal Transduction Pathway and Anti-diabetic Activity of Small Molecule Insulin Receptor Activators*

D. Moller, D. E. Biazzo-Ashnault, V. Ding, 2000, The Journal of Biological Chemistry.

Discovery of benzodihydroisofurans as novel, potent, bioavailable and brain-penetrant prolylcarboxypeptidase inhibitors.

Michael E. Lassman, Shirly Pinto, M. Garcia-Calvo, 2012, Bioorganic & medicinal chemistry letters.

C-terminal Loop Mutations Determine Folding and SecretionProperties of PCSK9

D. Johns, T. Vogt, D. Wisniewski, 2016 .

Tracking fatty acid kinetics in distinct lipoprotein fractions in vivo: a novel high-throughput approach for studying dyslipidemia in rodent models

D. Johns, J. Castro-Pérez, T. Roddy, 2013, Journal of Lipid Research.